Glenmark joins growing list of drugmakers to settle long-running US price-fixing claims

After handing over $30 million in criminal penalties last summer, Glenmark Pharmaceuticals has agreed to settle with the U.S. government over claims it fixed the price on a popular cholesterol medicine.